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Abstract
Background: The purpose of this study was to explore women’s views of the design of a large pragmatic cost-
effectiveness randomised controlled trial of the policy of offering a health professional-delivered intervention to
promote early presentation with breast symptoms in older women and thereby improve survival, with a view to
informing protocol development. The trial will recruit over 100,000 healthy women aged 67+, and outcome data
will be collected on those who develop breast cancer. The scale of the trial and the need for long-term follow-up
presented a number of design challenges in relation to obtaining consent, ascertaining and contacting participants
who developed breast cancer, and collecting outcome data.
Methods: Qualitative study involving 69 women participating in 7 focus groups and 17 in-depth interviews. 15
women had a previous diagnosis of breast cancer and 54 did not.
Results: The women held strong views and had a good understanding of the rationale of the design of clinical
trials. The women recognised that in a very large trial with long-term follow-up it was necessary to incorporate
design features to make the trial feasible and efficient. Most strikingly, they supported the idea of opt-out consent
and identifying women with breast cancer using routine datasets.
Conclusions: This model of user involvement engaged women well with the design challenges of the trial and
led to improvements to the protocol. The study strengthens the case for user involvement, in particular through
focus groups and in-depth interviews, in the design of trials.
Background
It is widely accepted that involving service users in the
design of research makes for more relevant research
questions, higher levels of participation, better study
design, and better interpretation of findings [1]. The
Department of Health Research Governance Framework
recommends that “relevant service users..... should be
involved wherever possible in the design, conduct, ana-
lysis and reporting of research” [2]. However, triallists
rarely report whether users have been involved in the
research and where they have, what happened as a result
[3], which makes it difficult to judge how useful the user
involvement was.
We have designed a randomised controlled trial to
evaluate the policy of offering a complex low-risk inter-
vention to promote early symptomatic presentation of
breast cancer in older women, and thereby improve sur-
vival. The intervention, known as the Promoting Early
Presentation (PEP) Intervention, consists of a 10-minute
interaction with a health professional supported by a
booklet. It is designed to provide older women with
information about the symptoms and risk of developing
breast cancer, and the motivation, confidence and skills
to present promptly on discovering a breast change
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[4,5]. The rationale is that a high proportion of older
women delay presentation with breast cancer [6] and
that this delay is associated with worse survival [7]. We
have already shown in a randomised controlled trial of
867 women that the intervention increases breast cancer
awareness at one year compared with usual care [8].
The hope is that the increased breast cancer awareness
(which encompasses motivation, confidence and skills as
well as knowledge) will lead to earlier presentation and
thereby improve survival.
We are now planning a much more ambitious cluster
randomised controlled trial which will examine whether
the policy of offering the PEP Intervention following
final routine mammogram on the National Health
Service (NHS) Breast Screening Programme (at the age
of 67-73) promotes prompt presentation and improves
survival compared with not offering the PEP Interven-
tion. The trial will need to recruit tens of thousands of
women over the whole of England because only a small
proportion of participants will develop breast cancer
(and, therefore, provide outcome data on duration of
symptoms and breast cancer survival) over the follow-
up period of five to eight years. We have chosen a clus-
ter design in this pragmatic trial to avoid the disruption
to services caused by individual randomisation in clinic,
and because there will be lower risk of missing potential
participants and of contamination. In addition, the PEP
Intervention must be delivered by a specially trained
radiographer; with individual randomisation, such a
radiographer would have to be present at every screen-
ing clinic, rather than simply at those in clusters rando-
mised to offer the PEP Intervention.
We incorporated a number of features into the design
of the trial to ensure that it would be feasible. These
related to the consent model and the methods of ascer-
taining, contacting and interviewing participants with
breast cancer.
Consent model
Individual trial participants can, potentially, give consent
to randomisation, participation and follow-up. Consent
from individuals to be randomised as a part of a cluster
in a trial is rarely possible [9,10]. Consent to participate
and be followed up are, on the other hand, possible and
desirable in a cluster-individual trial such as ours [11],
where individuals within clusters may be offered an
intervention (in contrast to a cluster-cluster trial where
the intervention may be applied to the whole cluster
with no real option for an individual to opt out, for
example, water fluoridation).
In our trial, because of the low risk associated with
participation, we proposed that consent to participate
and be followed up, in both control and intervention
arms, should be obtained using “opt-out” consent, rather
than the more traditional written opt-in consent. We
planned to seek this consent at the time of postal invita-
tion to participate sent with the invitation for a screen-
ing appointment, from women randomised both the
control and intervention arms. All participating women,
in both control and intervention arms would be pro-
vided with full written information about the trial,
including the contact details of a researcher with whom
to discuss participating if they wished, and would be
able to opt out of participating or being followed up by
post, telephone, online or in person when attending for
breast screening. If they opted out, they would remain a
member of relevant cluster (to be offered either the PEP
Intervention or not), but no data would be collected
about them and they would not be offered the PEP
Intervention should they be randomised to a cluster in
the PEP Intervention arm. We planned to obtain a
further level of informed consent from women in inter-
vention clusters to receive the PEP Intervention on arri-
val at the screening appointment: this would be opt-in
verbal consent (providing the woman had not opted out
earlier).
Methods of ascertaining, contacting and interviewing
participants with breast cancer
We proposed to identify trial participants who devel-
oped breast cancer by flagging their NHS numbers on
routine datasets, a method commonly used in trials to
identify deaths among participants [12]. This would be
minimally intrusive and would, therefore, also, minimise
cost. We proposed then to ask the women’s breast care
teams to seek consent from the women to be contacted
by our research team with a view to conducting an
interview to collect key outcome data on nature and
duration of symptoms. The reason for asking the breast
care team to coordinate consent for interviews is that
the clinicians would be able to judge the appropriate
timing of the interview and identify whether it might
have negative consequences for the woman - it is possi-
ble that the interview could cause distress, for example,
by resurrecting the fear and anxiety at the time of symp-
tom discovery or diagnosis or regret at having delayed
presentation.
We proposed to conduct interviews (having obtained
written opt-in consent), over the telephone rather than
face-to-face, at about eight to ten weeks after diagnosis.
These interviews would collect key outcome data: nature
and duration of symptoms. Other key outcome data in
the trial would be collected from cancer registry data,
for example, date of diagnosis and stage.
We wished to ensure that these proposed methods
were not considered a threat to the dignity, safety, rights
or well-being of the trial participants. We carried out a
qualitative study using focus groups and in-depth
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interviews to examine women’s perceptions of these
elements of trial design.
Methods
We carried out focus groups and in-depth interviews
with women aged 60 to 75, some who had been pre-
viously diagnosed with breast cancer and others who
had not had breast cancer. We recruited women with
breast cancer with the help of two cancer charities:
Macmillan, which advertised for volunteers on its web-
site, and Breast Cancer Care, which sent out a flyer with
its newsletter. We also directly contacted a Asian
women’s breast cancer support group. We recruited
women who had not had a previous diagnosis of breast
cancer using research recruitment agencies, who
approached women in public areas and from existing
databases of people willing to take part in research, to
invite them to participate. We aimed to achieve a mix
of women by age and income and living in rural and
urban locations.
During each focus group and interview, the facilitator
explained the trial design issues and used a topic guide.
In the focus groups, the facilitator supplemented this
with a vignette describing one imaginary trial partici-
pant’s experience of taking part in the trial (’Barbara’s
story’). All focus groups and interviews were audio-
recorded. We paid all participants £20 plus travel
expenses.
Interviews and focus groups were transcribed verbatim
and the data managed and analysed using the Frame-
work method [13]. This involved developing a thematic
framework, whereby columns represented themes and
rows represented an individual participant or groups of
participants. We summarised data from each participant
and/or group in the relevant cell (retaining the page of
the transcript from which it was taken, so that it was
possible to return to a transcript to explore a point in
more detail). We then identified patterns, explanations
and associations from the data.
The National Centre for Social Research Ethics Com-
mittee gave ethics approval for this qualitative study. All
participants provided verbal consent to take part.
Results
We carried out seven focus groups and seventeen
in-depth interviews in total. Table 1 shows the demo-
graphic characteristics of the women included in the
study. We achieved a good range of characteristics by
age, ethnic group, income, rural or urban residence and
living arrangements.
We carried out two focus groups and nine in-depth
interviews with women previously diagnosed with breast
cancer (total 15 participants). The focus groups were
held with two established groups of women, one based
in London and one in a market town in the Midlands: a
support group, and a volunteer group providing support
for women with breast cancer at a hospital. All these
women were of white British ethnic origin.
We carried out five focus groups (two in rural loca-
tions and three in London) and eight in-depth inter-
views with women who had not had breast cancer (total
54 participants). One of these focus groups was made
up of Bengali-speaking women. Four of the in-depth
interviews with women without breast cancer were with
Black British women.
The focus groups were held in private rooms in com-
munity centres and restaurants. The in-depth interviews
took place at the participants’ homes, except for two
with women diagnosed with breast cancer, which were
carried out over the telephone.
Consent model
Initial opt-out consent
The women (irrespective of experience of breast cancer,
ethnicity or location) expressed support for the opt-out
model for initial consent to participate and to be
followed up using routine datasets. The women
expressed understanding the need for trials to recruit a
high proportion of potential participants, that recruit-
ment should not be biased, and that trials had to be
cost-effective; they felt that opt-out consent would help
to achieve this. They also felt that opt-out consent
would be much easier for potential participants, and was
fair and inclusive. They thought that it might reduce
bias in recruitment: because women might otherwise be
inadvertently excluded simply because it was not conve-
nient at the time or easy to complete an opt-in form,
rather than because they really wished not to take part.
“I like the idea of opting out so then I’m included
and I won’t feel then left out or have to chase any-
body up to be in it.” (Focus group participant, No
breast cancer)
The women felt that the only reason they might wish
to opt out was because of the time commitment
involved in taking part, as they felt taking part in the
trial was not likely to be painful or intrusive.
Participants thought that it was sufficient to inform
women about the follow-up using routine datasets and
that seeking formal consent for this aspect of participa-
tion was unnecessary.
The idea of opt-out consent to being recontacted in
the event of developing breast cancer generated a more
mixed response. The women who had not had breast
cancer felt unsure about how they might feel about this
if they developed breast cancer. Some realised that even
if women opted out of being recontacted at recruitment
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to the trial, they might later change their mind. The
general view across the participants (regardless of char-
acteristics) was that any kind of consent (opt-in or
opt-out) for future contact at the time of recruitment
may not be valid several years later under different cir-
cumstances.
“Well, to be honest, until you’ve had cancer, you
don’t know, you can’t imagine how you feel. So you
might quite happily tick a box and say, ‘Yes if I get
cancer I’ll talk to you’, but again that might be a
different kettle of fish if you develop cancer. So I
don’t think you know yourself how you would cope
and how you would feel.” (Interview participant 1,
with breast cancer)
Opt-in verbal consent to receive the intervention
The women supported the idea of verbal consent to
receive the intervention. While comfortable with provid-
ing written consent, they expressed the view that the
main advantage of written over verbal consent was to
protect the researchers or the NHS, not the participants.
They said that written consent could be perceived as
too formal, which might inhibit people from taking part.
“I think I’d be quite happy just to be of any use or
any help, you know, in any way at all. And I
wouldn’t feel that I had to sign a piece of paper to
say yes I will do this. That’s almost being - I think
signing things is almost a bit more beholden.” (Inter-
view participant 2, with breast cancer)
They felt in that in a trial of this kind of intervention
written consent was not necessary, because the potential
for harm was low and that the participant would be
capable of making an informed decision to receive the
intervention or not.
The women recognised that written consent would
generate paperwork and this would incur costs and
storage issues.
“[written consent is] not really necessary is it? I
wouldn’t have thought so. I think verbal is fine. I
really do. I mean we’ve got enough paperwork any-
way. I know it doesn’t sound much but if you’re
doing thousands and thousands of women there’s a
cost to that you know, and I don’t see the point of it.
I really don’t.” (Interview participant 3, with breast
cancer)
The Bengali group noted that verbal consent might be
more valid for people who did not have a good com-
mand of written English, including those with a low
level of literacy in any language. In addition, they would
be able to provide consent without a family member, or
other, reading out written material to them, thus pro-
moting their confidentiality.
Informed consent
Several participants noted that consent to take part in
research, however it was given or recorded, would only
be valid if the participant was fully informed about the
implications of taking part. Indeed ensuring that
Table 1 Characteristics of participants
Characteristic Previous diagnosis of breast cancer
Yes No Total
Age 60 - 65 10 20 30
66 - 70 2 13 15
71 - 75 3 20 23
Unspecified 0 1 1
Ethnic group White British 14 36 50
Non-white 0 18 18
White other 1 0 1
Unspecified 0 0 0
Household income Under £20,000 6 20 26
£21,000 - £39,000 3 14 17
£40,000 and above 4 7 11
Unspecified 2 13* 15
Living arrangements Lives alone 6 15 21
Lives with partner 8 24 32
Lives with others 1 5 6
Unspecified 0 10* 10
Area London 5 36 41
Outside London 10 18 28
*These data were not collected from the ten women participating in the Bengali focus group.
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respondents felt informed was felt to be of greater sig-
nificance than the mode of consent gained - verbal or
written.
“It is important... just to keep people informed. In
most cases... if you’re not kept informed is when peo-
ple get cross and angry about things, ‘Well nobody
has told me this’...” (Interview participant 4, with
breast cancer)
Identification of women with breast cancer through
routine datasets
Participants recognised the need to identify women with
breast cancer through routine datasets in the context of
this trial and were generally comfortable with the idea.
There was some expectation, especially among the
women with breast cancer, that this was routinely done.
Participants felt that women should be informed in
clear language about the intention to follow them up
through routine datasets and the reasons for doing so.
Some expressed the view that it was important to out-
line specifically the plans for using the data.
“It has to be made clear in the beginning that if you
take part in this, we will use your date of birth and
your NHS number. We will then track you this year
and this year.” (Interview participant 4, with breast
cancer)
Participants had heard about losses of identifiable
electronic data held by the government. Some were con-
cerned that the routine datasets might not be stored
securely during the research but felt less concerned
knowing that the datasets would not contain names and
addresses, only NHS numbers. They felt that the risks of
retaining data were appropriately balanced against the
importance of the research. They felt the need for assur-
ances that the data would be used only for the purposes
of the trial, that access would be restricted to appropri-
ate research staff trained to handle and analyse the data
and that the data would not be available to pharmaceu-
tical or insurance companies.
Recontact to take part in an interview
The participants acknowledged that taking part in the
interview to collect data on the nature and duration of
symptom had the potential to lead to some negative
emotions. They generally approved of the idea that the
breast care team (in particular, a breast care nurse)
should coordinate making contact with a woman with
breast cancer to ask them to participate in an interview
to collect outcome data This was because the nurse
would be known and trusted, and could advise the
researchers about the appropriateness of contact at a
particular time. It was considered important that the
breast care team provided clear and concise information
about the nature of the interview to allow women to
make an informed decision about taking part.
Participants felt that women would be comfortable
declining to be contacted by the researchers and would
not feel an inappropriate level of obligation or pressure
to take part.
Women with breast cancer identified some disadvan-
tages of contact being coordinated by the breast care
team. Some had not experienced a high level of continu-
ity of care from their breast care teams, and thought
that women with similar experiences might find this
approach unacceptable.
Among the women with experience of breast cancer,
views about the proposed timing of recontact - eight to
ten weeks after diagnosis - varied. Some felt that this
timing was appropriate because women would probably
have recovered from the initial distress surrounding
diagnosis and that the interview might provide a wel-
come distraction during treatment. However, some felt
that this was too early because women might still be
having treatment or recovering. None felt that contact
should be made earlier than eight weeks after diagnosis.
Participants thought that the women should be able to
choose the timing of the interview.
Several participants thought that data on time from
symptom discovery to presentation should be collected
face-to-face rather than by a telephone interview. Some
participants thought that telephone interviewing would
be unpleasantly impersonal, but others suggested possi-
ble advantages of telephone interviewing: it might be
less embarrassing, less threatening, less time-consuming,
cheaper and more convenient if the woman was busy, ill
or living in a rural area.
Discussion
This qualitative study including focus groups and in-
depth interviews in women with and without personal
experience of breast cancer found broad support for an
unconventional consent model, a process of identifying
women with breast cancer using routine datasets and a
proposed method of recontact to take part in an inter-
view. We found limited support for the idea of collect-
ing data on nature and duration of breast cancer
symptoms using a telephone rather than a face-to-face
interview.
The results provided many insights leading to
improvements to the protocol and the information pro-
vided for participants. In particular, we gained support
for our proposal to seek opt-out consent for randomisa-
tion or follow-up using routine data; women did not see
this as a threat to their rights, safety or well-being.
However, seeking opt-out consent to be recontacted on
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developing breast cancer was not considered sufficient;
in fact, some expressed the view that consent of any
kind at recruitment to be recontacted some time later
under very different circumstances, in other words, in
the event of the woman developing breast cancer, might
not be valid, because she might feel very different about
it at that time - more positively or negatively disposed
towards it. We also gained support for the idea of verbal
consent to receive the intervention, once opt-out
consent to participate had been given.
In relation to follow-up using routine data, the results
suggested that not only did we need to develop robust
systems for data governance but also to reassure partici-
pants about these systems. It also suggested that we
should accommodate women’s choices about when to
be interviewed about nature and duration of symptoms
in the event of developing breast cancer. The study sug-
gested that face-to-face interviews with women to
collect data on the nature and duration of symptoms
might be seen to respect the well-being of participants
more effectively than telephone interviews.
We were surprised by the support for initial opt-out
consent to participate; we had expected participants to
think that this might lead to some women being
included against their will due to inertia or simply not
reading the postal materials. No participants expressed
this view: they felt that opt-out consent was inclusive
and cost-effective, and that it would help maximise par-
ticipation and reduce bias in recruitment. Their
responses suggested that they thought that these consid-
erations overrode the need for detailed opt-in consent.
This may be because the participants recognised that
the participants would not be asked to opt out of receiv-
ing the PEP Intervention, rather, they would be asked to
opt out of being offered the PEP Intervention (which
they would still be at liberty to decline) and to be fol-
lowed up using routine data. It is clear that consent to
receive any intervention should be obtained actively,
using opt-in methods (although not necessarily recorded
in writing) [14][15].
Opt-in consent may be seen as more defensible ethi-
cally and legally than opt-out consent as it relies on a
participant actively confirming that they have consented
(often by ticking or initialling a box and signing a form)
rather than solely omitting to withdraw consent. Opt-
out consent may be seen as a threat to participant
autonomy, a fundamental principle of medical ethics,
because failure to withdraw consent does not confirm
that the participant has actively consented. An opt-out
consent model has, however, been used with NHS
research ethics committee approval in trials of low risk
interventions [16]. Opt-out consent increases recruit-
ment and leads to less biased samples of participants and
has been recommended as the consent model of choice
for trials of this kind [17]. It is important in our trial that
we ensure that participants are provided with the option
of opting out at any time after initial recruitment.
A striking finding was the idea that written opt-in
consent was not always desirable and that verbal opt-in
consent might be preferable. The participants thought
that written opt-in consent was too formal, and that it
might inhibit women from taking part or make them
feel beholden to the researchers. They also felt that that
it protected the researchers or the NHS, not research
participants. The interpretation of written opt-in con-
sent as a contract or a liability waiver has been noted
before [18]. Another disadvantage of written consent
rather than verbal consent expressed was that it was less
likely to be valid in people of limited literacy or com-
mand of written English.
The guidance provided to National Health Service
Research Ethics Committees emphasises the importance
of achieving informed consent to take part in research,
rather than focusing on whether it is written or verbal,
or whether it is opt-in or opt-out http://www.nres.npsa.
nhs.uk/applications/guidance/consent-guidance-and-
forms/. Research ethics committee also refer to the
Department of Health guidance on consent to receive
physical interventions [15] (which the PEP Intervention
could, arguably, be seen to be, although it consists sim-
ply of a one-to-one discussion). This emphasises that
health professionals should assess capacity to consent,
ensure that consent is given voluntarily and ensure that
sufficient information is provided. The guidance is expli-
cit that the validity of consent does not depend on the
form in which it is given. It states that written consent
‘merely serves as evidence of consent; if the elements of
voluntariness, appropriate information and capacity have
not been satisfied, a signature on a form will not make
the consent valid’. There is no requirement in British
law for consent to be written (except for defined proce-
dures such as fertility treatment). Also relevant in the
UK is the General Medical Council’s guidance on consent
[14]. This also focuses on the need to provide full,
balanced information. This advises that consent for minor
or routine investigations or treatments may be verbal or
implied (for example, for phlebotomy or blood pressure
measurement). It also advises (although does not require)
that doctors obtain consent for treatments that are part of
a research programme. Whether the PEP Intervention
should be defined as a ‘treatment’ is not clear.
We were also surprised at the participants’ support for
the idea of identifying women with breast cancer using
routine datasets; we had expected that this would be
seen to be a threat to privacy given recent media cover-
age of losses of governmental electronic datasets includ-
ing identifiable data. However, this is consistent with
other findings [19][20].
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It was striking that the participants had a good under-
standing of the experimental nature of clinical trials.
This was in contrast to the findings of a Health Tech-
nology Assessment report on the public understanding
of randomised controlled trials, which suggested poor
public understanding of the rationale for the randomised
controlled trial design [21]. The participants in our
study recognised the need for trials to be conducted effi-
ciently, and that their primary aim was to answer the
research question; women did not find this difficult to
accept. This understanding may have been enhanced by
the lengthy introductory session to the interviews and
focus groups outlining the proposed trial which material
such as vignettes to promote participants’ comprehen-
sion. Such measures could be considered good practice.
The main limitation of our qualitative study may be
the representativeness of the participants. That women
were willing to participate in research of this kind sug-
gests that they were more educated about health
research than average. This may have meant that they
were less likely to find some aspects of trial design
unpalatable compared with the general female popula-
tion. Only five of the fifteen participants with breast
cancer were aged over 65, which we recognise as a lim-
itation, in view of the fact that the incidence of breast
cancer increases with age; this means that we may not
have adequately ascertained the views of older women
with breast cancer. Also, none of the women with breast
cancer belonged to non-white ethnic groups, so we were
unable to comment on the views of this group (although
these women represent a small proportion of the popu-
lation of the UK, and have a lower incidence of breast
cancer than white women [22]).
The most common forms of user involvement in ran-
domised controlled trials is in the drafting of trial infor-
mation leaflets and promoting recruitment, and users
sometimes sit on steering committees [3]. We have
found only a small volume of published evidence show-
ing that users can influence the design of randomised
controlled trials. The studies that we found describing
concrete changes to trial design as a result of the user
involvement used, like ours, focus groups and inter-
views. In the design of a trial of oxygen supplementation
after acute stroke, a quantitative and qualitative study of
people with stroke and their carers led to the identifica-
tion of the most appropriate outcome measures, clarified
the follow-up method to be used and influenced the
consent model [23]. During the design of a randomised
controlled trial of thrombolysis in acute stroke, a qualita-
tive study including focus groups to seek the views of
older people led to the design of a potentially controver-
sial consent model, including consent from next of kin
[24]. During the design of a trial to evaluate antiretroviral
and nutritional interventions to reduce mother-to-child
transmission of HIV during breastfeeding in Malawi,
an interview and focus group study of potential partici-
pants identified unforeseen potential problems with
trial implementation - for example, the propensity of
study participants to share out antiretroviral medica-
tion and food supplements given as part of the trial -
and led to identification of ways to minimise their
impact [25].
The focus group and in-depth interview model of user
involvement requires trained qualitative researchers, a
significant amount of work developing materials and
are, therefore, expensive. However, for our trial, using
this model generated surprising insights to strengthen
the protocol, which is, arguably, less likely to occur with
more common and conventional models of user involve-
ment such as sitting on steering groups.
Researchers are sometimes negative about user invol-
vement in trials, suggesting that it takes too long, that
expectations are too high, and that there is a conflict of
interest between the “role of a patient advocate and reli-
able assessment of cost-effectiveness” [3]. Using carefully
facilitated focus groups and in-depth interviews with
well-prepared materials, expectations of users were
appropriate and that there was no conflict of interest
between the role of the user and good study design.
Conclusions
A model of user involvement in research design,
employing focus groups and in-depth interviews,
engaged women well with the design challenges of the
trial and led to improvements to the protocol. The
study strengthens the case for user involvement of this
kind in the design of trials.
Opt-out consent to participate in trials is acceptable to
potential research participants and should be considered
for low risk interventions. Use of routine datasets is also
acceptable, given appropriate governance arrangements,
and should also be considered in trials where long term
follow up for relatively rare events is needed.
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